# National Cheng Kung University Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-cheng-kung-university-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 43.3 |
| Citations | 741,178 |
| City | Tainan City |
| Country | TW |
| Description | National Cheng Kung University Hospital is a research organisation in Tainan City, TW. OpenAlex records 14,905 works and 741,178 citations for it. 4,540 researchers list it as their most recent affiliation. |
| Homepage | http://www.hosp.ncku.edu.tw/nckm/english/HomeStyle.aspx?Type=11&ContentPage=0 |
| OpenAlex ID | https://openalex.org/I4210158999 |
| Researchers | 4,540 |
| ROR ID | https://ror.org/04zx3rq17 |
| Type | healthcare |
| Works | 14,905 |

## University papers

Showing 12 of 55.

- [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges](https://scholariq.org/papers/severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-and-coronavirus/)
- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/azd9291-in-egfr-inhibitor-resistant-non-small-cell-lung-cancer/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths](https://scholariq.org/papers/asymptomatic-carrier-state-acute-respiratory-disease-and-pneumonia-due-to-severe/)
- [Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial](https://scholariq.org/papers/afatinib-versus-placebo-for-patients-with-advanced-metastatic-non-small-cell/)
- [Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)
- [Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component](https://scholariq.org/papers/osimertinib-in-pretreated-t790m-positive-advanced-non-small-cell-lung-cancer/)
- [Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms](https://scholariq.org/papers/nanoparticles-in-the-treatment-of-infections-caused-by-multidrug-resistant/)
- [Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version.](https://scholariq.org/papers/development-and-verification-of-validity-and-reliability-of-the-whoqol-bref/)
- [An International Prospective Study of Pneumococcal Bacteremia: Correlation with In Vitro Resistance, Antibiotics Administered, and Clinical Outcome](https://scholariq.org/papers/an-international-prospective-study-of-pneumococcal-bacteremia-correlation-with/)

## University researchers

- [Jung‐Der Wang](https://scholariq.org/researchers/jung-der-wang/)
- [Chaw‐Ning Lee](https://scholariq.org/researchers/chaw-ning-lee/)
- [Ching‐Ju Fang](https://scholariq.org/researchers/ching-ju-fang/)
- [Jia‐Horung Hung](https://scholariq.org/researchers/jia-horung-hung/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.